Clinical efficacy and pharmacoeconomics of a continuous-infusion piperacillin-tazobactam program in a large community teaching hospital.
about
Continuous versus intermittent infusions of antibiotics for the treatment of severe acute infectionsRandomized, open-label, comparative study of piperacillin-tazobactam administered by continuous infusion versus intermittent infusion for treatment of hospitalized patients with complicated intra-abdominal infectionEvaluation by monte carlo simulation of the pharmacokinetics of two doses of meropenem administered intermittently or as a continuous infusion in healthy volunteers.Does prolonged β-lactam infusions improve clinical outcomes compared to intermittent infusions? A meta-analysis and systematic review of randomized, controlled trials.Nonlinear pharmacokinetics of piperacillin in healthy volunteers--implications for optimal dosage regimensClinical outcomes with alternative dosing strategies for piperacillin/tazobactam: a systematic review and meta-analysis.Stability and antibacterial activity of cefepime during continuous infusionSystematic comparison of the population pharmacokinetics and pharmacodynamics of piperacillin in cystic fibrosis patients and healthy volunteers.Strategies to enhance rational use of antibiotics in hospital: a guideline by the German Society for Infectious DiseasesContinuous versus intermittent administration of piperacillin-tazobactam in intensive care unit patients with ventilator-associated pneumoniaPharmacodynamics of antimicrobials: treatment optimisation.Application of antimicrobial pharmacodynamic concepts into clinical practice: focus on beta-lactam antibiotics: insights from the Society of Infectious Diseases Pharmacists.Clinical and microbiological efficacy of continuous versus intermittent application of meropenem in critically ill patients: a randomized open-label controlled trial.Pharmacodynamic optimization of beta-lactams in the patient care setting.Clinical outcomes of extended versus intermittent administration of piperacillin/tazobactam for the treatment of hospital-acquired pneumonia: a randomized controlled trial.Resistant pathogen-associated skin and skin-structure infections: antibiotic options.Using higher doses to compensate for tubing residuals in extended-infusion piperacillin-tazobactam.Carbapenem susceptibility breakpoints, clinical implications with the moving target.Continuous and Prolonged Intravenous β-Lactam Dosing: Implications for the Clinical Laboratory.Prolonged versus Intermittent Infusion of β-Lactams for the Treatment of Nosocomial Pneumonia: A Meta-Analysis.Clinical Outcomes of Extended Versus Intermittent Infusion of Piperacillin/Tazobactam in Critically Ill Patients: A Prospective Clinical Trial.Evaluation of an alternative extended-infusion piperacillin-tazobactam dosing strategy for the treatment of gram-negative infections.Continuous versus intermittent piperacillin/tazobactam infusion in infection due to or suspected pseudomonas aeruginosa.Synergy of daptomycin with oxacillin and other beta-lactams against methicillin-resistant Staphylococcus aureusContinuous infusion of antibiotics in the critically ill: The new holy grail for beta-lactams and vancomycin?Optimal dosing of piperacillin-tazobactam for the treatment of Pseudomonas aeruginosa infections: prolonged or continuous infusion?Use of Monte Carlo simulation to design an optimized pharmacodynamic dosing strategy for meropenem.Pharmacodynamics of meropenem and imipenem against Enterobacteriaceae, Acinetobacter baumannii, and Pseudomonas aeruginosa.Standard versus prolonged doripenem infusion for treatment of gram-negative infections.Continuous versus intermittent infusion of prophylactic cefoxitin after colorectal surgery: a pilot study.Population pharmacokinetics and pharmacodynamics of piperacillin/tazobactam in patients with complicated intra-abdominal infection.Treatment of Serratia marcescens meningitis with prolonged infusion of meropenem.
P2860
Q24199096-ED0495D5-0B88-486B-8AD7-31D453680D8AQ24675002-BC23D1B1-D1FB-4F91-9F3F-690E3E793193Q33770046-ACA9F3FB-3C2D-4131-B2EC-AD37E365F09AQ33940174-C77CFEE3-E9C2-4D08-B089-B96A26CB5D87Q34381321-3753724D-E785-4BB5-B484-91F86916F9C7Q34892334-F32D31E6-7B7A-46A1-AC0B-6B97FB933A34Q35014076-C25C9EB4-4235-4E92-8843-B2041B9D2FD0Q35878860-2856A685-961D-4F7B-AF01-7A8B19302F42Q35986250-10EA6E04-CC3C-47E4-864B-CB0BA1F94E88Q36422575-4811D5C9-92E2-4761-B5E6-790D3233E46FQ36544935-E69A93A0-6C3B-4101-947D-A690B7BE3DE8Q36582692-3D1F250C-4B69-40FF-9FC4-FA218C407456Q36633761-5BC98D2D-24C6-4CF7-B5DB-20F6C45527E6Q37169843-99AE5134-70F2-4D31-8C8A-5A7CF697933CQ37642084-2DE591CE-4254-4C48-82D1-74FFFB566E16Q37785546-644FA519-AB90-4F7C-A316-303CE956C2E7Q38110142-E27F4DF9-1B4A-4BA6-B542-52FEC23F6AB5Q38751264-55470E58-7CA1-423F-9059-A0A487EDA24FQ38896040-19CF8458-F88F-4547-9B33-547543CC9293Q39586044-AD549B12-BD43-4E01-82FA-EFC5E66E26A6Q40078698-88EC993B-95D6-42CE-A582-4D42394B683CQ40687385-F5371A5A-6011-4F93-9207-35DBEE011231Q40948657-4F7CD43F-9D18-4B31-849B-DD70707F9DF1Q41269406-A33C773E-C346-46B4-9859-996D9D168877Q42432137-66F8E480-8DE2-4871-9D33-4216AC8EFE89Q44235811-B77C2467-65DB-413D-B181-B3D77124632BQ44601141-61B78B58-03AC-4707-914D-D1CA2C55E3ECQ44740259-AECF7634-E88A-4771-ACF9-5CC09C9A882EQ46357807-DB6C2DA4-724A-4F9C-9963-CF3A2203CE65Q46408015-BE9CFECA-261A-473D-ABA3-B6F87BCCBD1DQ46588566-9C43BB06-CE84-4E07-BC3F-3F15285D6BC3Q51754688-97EEB58A-A1ED-4B07-A237-4BE5BBF898E4
P2860
Clinical efficacy and pharmacoeconomics of a continuous-infusion piperacillin-tazobactam program in a large community teaching hospital.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
2002年论文
@zh
2002年论文
@zh-cn
name
Clinical efficacy and pharmaco ...... e community teaching hospital.
@en
type
label
Clinical efficacy and pharmaco ...... e community teaching hospital.
@en
prefLabel
Clinical efficacy and pharmaco ...... e community teaching hospital.
@en
P2093
P2860
P1433
P1476
Clinical efficacy and pharmaco ...... e community teaching hospital.
@en
P2093
Charles Nightingale
David P Nicolau
Edward M Grant
Joseph L Kuti
Richard Quintiliani
P2860
P304
P356
10.1592/PHCO.22.7.471.33665
P407
P577
2002-04-01T00:00:00Z